UCI-101

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameUCI-101
Drug Alias Nameanti-CD19 + anti-CD22 CAR-NK cell therapy (UCI Therapeutics/Daewoong Pharmaceutical)UCI-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionCD22 modulatorsB-lymphocyte antigen CD19 modulatorsImmunostimulants +[4] 
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUCI Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUCI Therapeutics IncDaewoong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A